12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Company News  |  Deals

Sequella, Pfizer deal

Pfizer granted Sequella exclusive, worldwide rights to develop and commercialize the pharma's sutezolid, which is in Phase II testing to treat tuberculosis (TB). Sequella said it plans to develop the oxazolidinone antibiotic alone for TB and in combination with the...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >